Loading
קמהדע is a listed company. Its insiders report their share dealings to TASE (ISA). Between 18 October 2025 and 18 October 2026, 7 insiders published 7 filings.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
There has been no open-market purchase by an insider of קמהדע for at least a year.
Compared with its exchange (530 companies, median 14 filings), a count of 7 filings is below the norm.
These figures are compiled from regulatory filings published by TASE (ISA). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
7 of 7 declarations
Kamada is a biopharmaceutical company focused on the development and commercialization of therapeutic products based on proteins. It is listed on the Tel Aviv Stock Exchange.